Bure Equity AB (publ) BURE
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position can be maintained pending further confirmation of portfolio development.
Significant NAV growth in Q2 but the share still trades at a discount to net asset value which supports a neutral stance.
The market reacts positively to the strong NAV development and the remaining discount to net asset value.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 6 Jun 2026 — The latest analysis adds Q1 reporting: a weak quarter (NAV −9% YTD and a large net loss) followed by a clear post-quarter NAV rebound.
About the company
Bure Equity is an investment company focused on long-term ownership in Nordic companies with emphasis on technology and healthcare. The portfolio is dominated by listed holdings such as Mycronic, Vitrolife, Silex Microsystems and Xvivo Perfusion. Value development is driven by the share price performance of portfolio companies and net asset value.
Bull case
Strong NAV growth in Q2 2026 driven by Mycronic and the Silex listing creates momentum.
Bear case
High concentration in a few large holdings makes the company sensitive to individual share price movements.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Mycronic share price | Mycronic share price falls sharply → net asset value declines rapidly and the discount may widen. | Mycronic share price continues to rise → net asset value increases further and may lead to a premium. |
| Silex Microsystems development | Silex performs weakly after listing → contribution to NAV decreases and negatively affects total return. | Silex continues strongly → additional value increase in the portfolio and strengthened confidence in the listing strategy. |
Why this signal
Significant NAV growth in Q2 but the share still trades at a discount to net asset value which supports a neutral stance.
Recent news
Q2 report showed a 41 percent increase in net asset value, mainly driven by Mycronic and Silex. The share trades at approximately 15 percent discount to the updated NAV. Investtech issued a technical buy recommendation in mid-September and Bure ranked among the most added stocks by retail investors.